PMID- 32770843
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20221207
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 75
IP  - 1
DP  - 2021 Jan
TI  - The perspectives of physicians regarding antidiabetic therapy de-intensification 
      and factors affecting their treatment choices-A cross-sectional study.
PG  - e13662
LID - 10.1111/ijcp.13662 [doi]
AB  - AIMS: Comprehensive diabetes management may include treatment intensification or 
      the administration of antidiabetic combination therapy. However, this may be 
      associated with an increased risk of adverse events and death. The aim of this 
      study was to understand physicians' perspectives regarding treatment 
      de-intensification, HbA1c goals individualisation, and factors affecting their 
      treatment choice for patients with type 2 diabetes mellitus (T2DM). METHODS: A 
      cross-sectional study was conducted in primary and secondary care units in Saudi 
      Arabia using online questionnaire. Two previously validated questionnaires were 
      used to understand physicians' awareness of, agreement with, and their practices 
      of individualising HbA1c goals and antidiabetic treatment optimisation, and to 
      assess factors affecting physicians' treatment choice when prescribing 
      antidiabetic treatment for patients with type 2 diabetes mellitus. Study 
      population were physicians who are treating patients with diabetes mellitus 
      during the period between October 2017 and May 2018. RESULTS: A total of 205 
      physicians have participated in the study. Approximately 50% of physicians had 
      family medicine speciality (n = 98, 47.8%). The majority of physicians (n = 183, 
      89.3%) were familiar with the concept of HbA1c goals individualisation. However, 
      only 66.3% of them (n = 136) reported that they apply it either always or most of 
      the time. 58.5% (n = 120) of physicians reported that they would not initiate 
      conversations about de-intensifying antidiabetic therapy even if their patients 
      had a stable HbA1c values for one year. Physicians showed higher consideration to 
      objective patient clinical data and their assessment of patient's health status, 
      with minor consideration to patient-related factors. CONCLUSIONS: Healthcare 
      professionals should focus more on implementing contemporary practices and 
      applying any necessary treatment de-intensification or dose adjustment. 
      Subjective patient factors should be taken into account further, as these factors 
      are associated with better disease management.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Naser, Abdallah Y
AU  - Naser AY
AUID- ORCID: 0000-0001-8440-7446
AD  - Department of Applied Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, 
      Isra University, Amman, Jordan.
FAU - Alsairafi, Zahra
AU  - Alsairafi Z
AD  - Department of Pharmacy Practice, Kuwait University, Kuwait, Kuwait.
FAU - Alwafi, Hassan
AU  - Alwafi H
AD  - Faculty of Medicine, Umm Alqura University, Mecca, Saudi Arabia.
AD  - Research Department of Practice and Policy, UCL School of Pharmacy, London, UK.
FAU - Mohammad Turkistani, Fawaz
AU  - Mohammad Turkistani F
AD  - Al Noor Specialist hospital, Ministry of Health, Mecca, Saudi Arabia.
FAU - Saud Bokhari, Nedaa
AU  - Saud Bokhari N
AD  - Al Noor Specialist hospital, Ministry of Health, Mecca, Saudi Arabia.
FAU - Alenazi, Badi
AU  - Alenazi B
AD  - Paediatric Department, Alyamamah hospital, Riyadh, Saudi Arabia.
FAU - Zmaily Dahmash, Eman
AU  - Zmaily Dahmash E
AD  - Department of Applied Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, 
      Isra University, Amman, Jordan.
FAU - Alyami, Hamad S
AU  - Alyami HS
AD  - Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, 
      Saudi Arabia.
LA  - eng
GR  - Najran University and Cancer Society in Najran/
PT  - Journal Article
DEP - 20200903
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Physicians
MH  - Saudi Arabia
EDAT- 2020/08/10 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/07/09 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - 10.1111/ijcp.13662 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2021 Jan;75(1):e13662. doi: 10.1111/ijcp.13662. Epub 2020 Sep 
      3.